Dramatic improvement of DC-based immunotherapy against various malignancies.

  title={Dramatic improvement of DC-based immunotherapy against various malignancies.},
  author={Yui Harada and Yoshikazu Yonemitsu},
  journal={Frontiers in bioscience},
Dendritic cells (DCs) play a crucial role in maintaining the immune system. Though DC-based cancer immunotherapy has been suggested as a potential treatment for various kinds of malignancies, clinical efficacies are still insufficient in many human trials. To identify the causes of the low efficacies, we paid attention to their numbers and how they are activated. We proved that DCs' antitumor effect depends on their number and the way they are activated. We here established a possible… 
Tumor progression-related transmembrane protein aspartate-β-hydroxylase is a target for immunotherapy of hepatocellular carcinoma.
It is found that immunotherapy with ASPH-loaded DCs suppressed and delayed established HCC and tumor growth when administered prophylactically, and has substantial anti-tumor effects which could reduce the risk of HCC recurrence.
Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency
Oncolytic paramyxoviruses include some strains of Measles, Mumps, Newcastle disease, and Sendai viruses. All these viruses are well equipped for promoting highly specific and efficient malignant cell
In vitro transfection of bone marrow-derived dendritic cells with TATp-liposomes
It is shown that the addition of TATp to DNA-loaded liposomes increased the uptake of DNA in DC and increased the in vitro transfection efficiency in DC cultures.
Psycho-immunological rehabilitation of advanced cancer patients with psychogenic medical history
Clinical opportunities of positive influence of special psycho-immunological rehabilitation on to the course of a disease of advanced cancer patients with psychogenic medical history are shown.
Advanced Cancer Treatment – An Original Approach


Sustained and NK/CD4+ T Cell-Dependent Efficient Prevention of Lung Metastasis Induced by Dendritic Cells Harboring Recombinant Sendai Virus1
These results are the first demonstration of efficient inhibition of lung metastasis via bolus administration of virally activated DCs that was sustained and NK/CD4+ cell-dependent, and may suggest a potentially new mechanism of DC-based immunotherapy for advanced malignancies.
Dendritic-cell-based therapeutic vaccination against cancer.
Early clinical trials, in which over 1000 cancer patients received dendritic cell vaccines, tested different vaccine preparations, but they did not always induce sufficient acquired immunity or meet the expected level of tumor regressions, explaining the current need for innovative well designed trials with defined endpoints that induce robust anti-tumor immunity.
Dendritic cells as therapeutic vaccines against cancer
The immunogenicity of antigens delivered by dendritic cells has now been shown in patients with cancer, and a better understanding of how dendrites regulate immune responses will allow us to better exploit these cells to induce effective antitumour immunity.
Cytokine-Based Log-Scale Expansion of Functional Murine Dendritic Cells
A simple and cytokine-based culture method is established to realize a log-scale order of functional murine DCs, which cells were used as a model before moving to human studies and had typical features of conventional myeloid DCs in vitro and in vivo.
Dendritic cell immunotherapy: mapping the way
Although early clinical trials indicate that DC vaccines can induce immune responses in some cancer patients, careful study design and use of standardized clinical and immunological criteria are needed.
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Vaccination with autologous DCs generated from peripheral blood is a safe and promising approach in the treatment of metastatic melanoma and antigen-specific immunity was induced during DC vaccination.
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
In this pilot study, we investigated the ability of autologous dendritic cells pulsed ex vivo with tumor–specific idiotype protein to stimulate host antitumor immunity when infused as a vaccine. Four
Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy
The data show that the tumor did not spontaneously induce or maintain an activated CTL response, revealing a profound lack of immunogenicity in vivo, and repetitive immunizations are necessary for prolonged antitumor immunotherapy.
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
Treatment of animals bearing established macroscopic tumours with tumour peptide-pulsed dendritic cells resulted in sustained tumour regression and tumour-free status in more than 80% of cases, and support the clinical use of tumour Peptide-Pulsed Dendritic Cells as components in developing effective cancer vaccines and therapies.
GM-CSF in the generation of dendritic cells from human blood monocyte precursors: recent advances.
The finding that human DCs can be generated from monocytes in the presence of granulocyte/macrophage colony-stimulating factor (GM-CSF) alone points to this cytokine as a direct player, rather than a survival-promoting factor, in the development of DCs with distinct properties.